boceprevir
Sign in to saveAlso known as SCH-503034, SCH 503034
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. It binds to the HCV nonstructural protein 3 active site.
Research
1,154 papers- Boceprevir.Drugs of today (Barcelona, Spain : 1998) · 2011
- Boceprevir.Drugs in R&D · 2010
- Boceprevir.Hepatology (Baltimore, Md.) · 2011
- Boceprevir: a user's guide.Clinics in liver disease · 2011
- Boceprevir.Prescrire international · 2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 519.34207
- Has use
- medication
Show 9 more facts
- chemical formula
- C₂₇H₄₅N₅O₅
- canonical SMILES
- CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
- isomeric SMILES
- CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
- World Health Organisation international non-proprietary name
- boceprevir
- defined daily dose
- 2.4
- medical condition treated
- liver cirrhosis
- physically interacts with
- Cathepsin A
- Commons category
- Boceprevir
- subject has role
- bactericide
Sources (6)
via Wikidata · CC0
~5 min read
Encyclopedic overview
6 sectionsContents
- Clinical trials
- SPRINT-1 trial
- SPRINT-2 trial
- RESPOND-2 trial
- See also
- References
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. It binds to the HCV nonstructural protein 3 active site.
It was initially developed by Schering-Plough, then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. In January 2015, Merck announced that they would be voluntarily withdrawing Victrelis from the market due to the overwhelming superiority of newer direct-acting antiviral agents, such as ledipasvir/sofosbuvir.
Excerpted from Wikipedia’s “boceprevir” article, available under the CC BY-SA 4.0 licence.